<DOC>
	<DOCNO>NCT00674700</DOCNO>
	<brief_summary>The purpose study assess efficacy two dos sublingual immunotherapy ( SLIT ) administer allergen-based tablet daily period 12 month compare placebo , reduction allergic rhinitis symptom rescue medication usage</brief_summary>
	<brief_title>Safety Efficacy Study Sublingual Immunotherapy ( SLIT ) Treat House Dust Mite Allergic Rhinitis</brief_title>
	<detailed_description>Allergic rhinitis high-prevalence disease many developed country , affect 10 20 % general population . House dust mite allergen know cause perennial allergic rhinitis . In design present study , guideline propose World Allergy Organization ( WAO ) task force methodology immunotherapy study take consideration . After 2-month screening period , patient administer dose 300 IR- 500 IR-house dust mite allergen-based tablet placebo period 12 month . The carry-over effect evaluate treatment-free follow period 12 month .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>1 . Male female outpatient age 18 50 year ( inclusive ) . 2 . Patients informed nature aim study give write consent 3 . Patients must general good health determine past medical history , physical examination safety laboratory test . 4 . Female patient childbearing potential eligible 5 . Negative urine pregnancy test female patient childbearing potential . 6 . House dust miterelated allergic rhinitis least 1 year . 7 . Sensitised D. pteronyssinus D. farinae ( positive SPT wheal diameter great 3 mm specific IgE level â‰¥ 0.7 kU/L ) . 8 . Baseline ARTSS &gt; 5 ( completion 7day daily record card ) . 9 . Patients willing comply protocol . 10 . Patients able understand information give text consent form , able complete daily record card RQLQ . 1 . Whatever consider allergen , cosensitisation lead clinically relevant allergic rhinitis , sinusitis , conjunctivitis asthma likely significantly change symptom patient throughout study ( mean patient symptomatic another allergen house dust mite ) . 2 . Patients nasal condition could confound efficacy safety assessment ( example nasal polyposis ) . 3 . Patients sensitise cat dog allergens live animal home . 4 . Pregnant , breastfeed / lactate sexually active woman childbearing potential use medically accept contraceptive method . 5 . Asthma require treatment beta2 inhaled agonist . Patients intermittent asthma necessitating inhaled systemic corticoid treatment may include ( correspond Global Initiative Asthma [ GINA ] Step 1 ) . 6 . Patients treated systemic , nasal inhaled steroid ( whatever indication ) within 4 week Visit 1 . 7 . Patients treat long acting systemic steroid ( whatever indication ) within 12 week Visit 1 Visit 2 . 8 . FEV1 &lt; 80 % predict value Visit 1 . 9 . Patients receive allergy specific immunotherapy house dust mite last 10 year . 10 . Patients risk noncompliance . 11 . Participation clinical study within 12 week Visit 1 . 12 . Investigators , coinvestigators , well child spouse study collaborator enrol study . 13 . Any change environmental measure allergen avoidance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>House dust mite allergy</keyword>
</DOC>